Those that expressed MYD88 mutations did not demonstrate differences in median overall survival, time to next therapy from frontline treatment, or median time to progression to active disease in those with smoldering Waldenström macroglobulinemia. The gene discussed is MYD88; the disease is Waldenstrom macroglobulinemia.